Navigation Links
Oncomine(TM) Again Key to Prostate Cancer Discovery
Date:6/10/2008

Cancer Cell Report Identifies SPINK1 as a New Biomarker for Prostate Cancer

ANN ARBOR, Mich., June 10 /PRNewswire/ -- Compendia Bioscience, Inc., the leading provider of cancer profiling data and analysis tools, today announced the central role of their flagship product Oncomine(TM) in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer.

Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number arrays coupled with analysis functions and a web application for data mining and visualization. Comprised of thousands of samples representing every major type of cancer, Oncomine exploits this data for therapeutic target discovery, validation, and prioritization.

Compendia CEO Daniel R. Rhodes, Ph.D., in his continued role as a research investigator at the University of Michigan, led the Oncomine analysis that identified SPINK1 as a candidate oncogene in prostate cancer. Further experimental work by many of the same scientists that previously identified ETS-family gene fusions in prostate cancer using Oncomine led to this discovery.

"We extended an approach called Cancer Outlier Profile Analysis (COPA) that had previously led us to identify ETS-family gene fusions in prostate cancer," said Dr. Rhodes. "We knew from that experience that true oncogenes are likely to appear in COPA results from multiple independent datasets. Therefore, we intentionally looked for genes that had high COPA ranks across multiple datasets and SPINK1 looked interesting. Further Oncomine analysis showed that SPINK1 over-expression was mutually exclusive with ETS-family gene fusion events and was not present in normal prostate tissue. So, we were pretty sure we had found something important."

Published in the current edition of Cancer Cell (Volume 13 Issue 6: June 2008), this study shows that SPINK1 is detectable in the urine and that SPINK1-positive prostate cancers are a particularly aggressive molecular subset of prostate cancer with SPINK1 having a role in cancer invasion.

The analysis approach used to identify SPINK1 has been named Meta-COPA and will soon become a standard feature within the Oncomine platform. In the interim, Compendia Bioscience will provide scientific services to answer customers' key research questions requiring Meta-COPA or other analyses not currently addressable through the Oncomine user interface.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. The Oncomine Platforms are used by thousands of cancer researchers worldwide in both academic institutions as well as biotech and pharmaceutical companies to advance the molecular understanding of cancer and cancer treatment. http://www.compendiabio.com


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition
2. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
5. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
9. Sticky mussels inspire biomedical engineer yet again
10. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
11. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... , ... September 20, 2017 ... ... published findings of a study examining the effects of exoskeleton-assisted walking on ... cord injury (SCI). The article, "Neuromechanical adaptations during a robotic powered exoskeleton ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of ... a high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered ... ducted hoods in the laboratory. , Attendees will learn from an industry expert ...
(Date:9/19/2017)... FRANCISCO , Sept. 19, 2017 ValGenesis ... Solutions (VLMS) is pleased to announce the strategic partnership ... to provide clients with validation services using the latest ... partner, VTI will provide clients with efficient and cost-effective ... a marketing partner for the ValGenesis VLMS system. ...
(Date:9/18/2017)... ... 2017 , ... Transportable biomass conversion facilities and the economics ... the topic of a September 27 webinar hosted by the Waste ... biomass conversion facilities for producing biochar, briquettes, and torrefied wood, biomass supply chains ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):